SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sonja Klebe, Jack Driml, Masaki Nasu, Sandra Pastorino, Amirmasoud Zangiabadi, Douglas Henderson, Michele Carbone, BAP1 hereditary cancer predisposition syndrome: a case report and review of literature, Biomarker Research, 2015, 3, 1, 14

    CrossRef

  2. 2
    Francesco Piva, Matteo Santoni, Marc R Matrana, Suma Satti, Matteo Giulietti, Giulia Occhipinti, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Giovanni Principato, Stefano Cascinu, Rodolfo Montironi, BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies, Expert Review of Molecular Diagnostics, 2015, 1

    CrossRef

  3. 3
    K. Rai, R. Pilarski, C.M. Cebulla, M.H. Abdel-Rahman, Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases, Clinical Genetics, 2015, 88, 3
  4. 4
    Lauren G. Aoude, Karin A. W. Wadt, Antonia L. Pritchard, Nicholas K. Hayward, Genetics of familial melanoma: 20 years after CDKN2A, Pigment Cell & Melanoma Research, 2015, 28, 2
  5. 5
    Marta Betti, Elisabetta Casalone, Daniela Ferrante, Antonio Romanelli, Federica Grosso, Simonetta Guarrera, Luisella Righi, Simona Vatrano, Giuseppe Pelosi, Roberta Libener, Dario Mirabelli, Renzo Boldorini, Caterina Casadio, Mauro Papotti, Giuseppe Matullo, Corrado Magnani, Irma Dianzani, Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area, Genes, Chromosomes and Cancer, 2015, 54, 1
  6. 6
    F. Baumann, E. Flores, A. Napolitano, S. Kanodia, E. Taioli, H. Pass, H. Yang, M. Carbone, Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival, Carcinogenesis, 2015, 36, 1, 76

    CrossRef

  7. 7
    Andreas Rusch, Gabriela Ziltener, Kristiaan Nackaerts, Walter Weder, Rolf A. Stahel, Emanuela Felley-Bosco, Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases, Lung Cancer, 2015, 87, 1, 77

    CrossRef

  8. 8
    Lauren G. Aoude, Michael Gartside, Peter Johansson, Jane M. Palmer, Judith Symmons, Nicholas G. Martin, Grant W. Montgomery, Nicholas K. Hayward, Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases, Twin Research and Human Genetics, 2015, 18, 02, 126

    CrossRef

  9. 9
    Anna E Koopmans, Robert M Verdijk, Rutger W W Brouwer, Thierry P P van den Bosch, Mike M P van den Berg, Jolanda Vaarwater, Christel E M Kockx, Dion Paridaens, Nicole C Naus, Mark Nellist, Wilfred F J van IJcken, Emine Kiliç, Annelies de Klein, Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma, Modern Pathology, 2014, 27, 10, 1321

    CrossRef

  10. 10
    T. H. van Essen, S. I. van Pelt, M. Versluis, I. H. Bronkhorst, S. G. van Duinen, M. Marinkovic, W. G. Kroes, C. A. Ruivenkamp, S. Shukla, A. de Klein, E. Kilic, J. W. Harbour, G. P. Luyten, P. A. van der Velden, R. M. Verdijk, M. J. Jager, Prognostic parameters in uveal melanoma and their association with BAP1 expression, British Journal of Ophthalmology, 2014, 98, 12, 1738

    CrossRef

  11. 11
    Jasmine H. Francis, David H. Abramson, Update on Ophthalmic Oncology 2013, Asia-Pacific Journal of Ophthalmology, 2014, 3, 4, 241

    CrossRef

  12. 12
    Tero Kivelä, Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies, 2014,

    CrossRef

  13. 13
    Bertil Damato, Sarah E Coupland, Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies, 2014,

    CrossRef

  14. 14
    Mitchell Cheung, Jacqueline Talarchek, Karen Schindeler, Eduardo Saraiva, Lynette S. Penney, Mark Ludman, Joseph R. Testa, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma, Cancer Genetics, 2013, 206, 5, 206

    CrossRef

  15. 15
    Douglas B. Johnson, Jeffrey A. Sosman, Update on the Targeted Therapy of Melanoma, Current Treatment Options in Oncology, 2013, 14, 2, 280

    CrossRef